- XBiotech (NASDAQ:XBIT) has completed enrollment in its Phase 2, open label clinical study evaluating subcutaneous administration of bermekimab in patients with moderate to severe Atopic Dermatitis (AD).
- The Phase 2 study consists of two dose cohorts. Nine patients in the first dosing cohort received a total of 4 weekly 200mg injections of bermekimab followed by safety assessments. Patients in the second cohort will receive 8 weekly 400mg injections of bermekimab for assessment of safety and preliminary efficacy.
- XBiotech has now exceeded enrollment in the final cohort of patients.